GH Dec 2022 165.000 call
- Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
REDWOOD CITY, Calif., May 26, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
- Business Wire
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
PALO ALTO, Calif. & BARCELONA, Spain, May 25, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing facility in Barcelona.
- Business Wire
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
PALO ALTO, Calif., May 23, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations highlighting the use of real-world data to identify resistance to early treatment in advanced breast cancer and the use of enhanced biomarker analysis to evaluate progression-free survival data in metastatic
